<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="chapter-article"><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><?noissn?><front><journal-meta><journal-id journal-id-type="publisher-id">978-3-7091-1496-4</journal-id><journal-id journal-id-type="doi">10.1007/978-3-7091-1496-4</journal-id><journal-id journal-id-type="nlm-ta">Noninvasive Ventilation in High-Risk Infections and Mass Casualty Events</journal-id><journal-title-group><journal-title>Noninvasive Ventilation in High-Risk Infections and Mass Casualty Events</journal-title></journal-title-group><isbn publication-format="print">978-3-7091-1495-7</isbn><isbn publication-format="electronic">978-3-7091-1496-4</isbn></journal-meta><article-meta><article-id pub-id-type="pmcid">7120172</article-id><article-id pub-id-type="publisher-id">14</article-id><article-id pub-id-type="doi">10.1007/978-3-7091-1496-4_14</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Noninvasive Ventilation in Patients with Acute Respiratory Failure Due to Influenza A(H1N1) Virus Infection</article-title></title-group><contrib-group content-type="book editors"><contrib contrib-type="editor"><name><surname>Esquinas</surname><given-names>Antonio M.</given-names></name><address><email>antmesquinas@gmail.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="GRID">grid.411101.4</institution-id><institution-id institution-id-type="ISNI">0000000417655898</institution-id><institution>Intensive Care &#x00026; Non Invasive Ventilatory Unit, </institution><institution>Hospital Morales Meseguer, </institution></institution-wrap>Murcia, Spain </aff></contrib-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Belenguer-Muncharaz</surname><given-names>Alberto</given-names></name><degrees>MD</degrees><address><email>belenguer_alb@gva.es</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff2"><label>2</label>Servicio de Medicina Intensiva, Intensive Care Unit, Hospital Universitario General de Castell&#x000f3;n, Castell&#x000f3;n, Spain </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.470634.2</institution-id><institution>SMI Hospital General, </institution></institution-wrap>Av Benicassim s/n, 12004 Castell&#x000f3;n, Spain </aff></contrib-group><pub-date pub-type="epub"><day>29</day><month>5</month><year>2013</year></pub-date><fpage>139</fpage><lpage>143</lpage><permissions><copyright-statement>&#x000a9; Springer-Verlag Wien 2014</copyright-statement><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p></license></permissions><abstract id="Abs00141"><p>During the type &#x02018;A&#x02019; Influenza epidemic (&#x02018;swine flu&#x02019;), most of the patients admitted to the intensive care unit (ICU) required assisted ventilation because of an acute respiratory failure (ARF). Noninvasive ventilation (NIV) was used in varying proportions in the published series, but it showed a high failure rate. In our series &#x02014; specifically in a group of hypoxemic patients &#x02014; NIV was employed successfully in all cases without any hypoxemia-related deaths. Accordingly, we recommend NIV can be applied to healthy young hypoxemic patients before considering invasive mechanical ventilation (IMV).</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Noninvasive ventilation</kwd><kwd>Pandemic</kwd><kwd>Influenza A(H1N1)</kwd><kwd>Pneumonia</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag Wien 2014</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec00141" sec-type="introduction"><title>Introduction</title><p>Viruses are an age-old foe of humans and have caused great loss of life on a global scale. For example, the &#x0201c;Spanish flu&#x0201d; outbreak (1918&#x02013;1919) caused 50 million deaths worldwide [<xref ref-type="bibr" rid="CR00141">1</xref>]. RNA viruses of the Family Orthomyxoviridae [<xref ref-type="bibr" rid="CR00142">2</xref>]&#x02014;including the influenza A(H1N1) virus&#x02014;have caused many epidemics. The virus undergoes constant genetic changes and gave rise to the new H1N1 (swine flu or type A influenza), which started the pandemic that began in Mexico in 2009.</p><p>A published series [<xref ref-type="bibr" rid="CR00143">3</xref>&#x02013;<xref ref-type="bibr" rid="CR00147">7</xref>] showed that patients admitted to the intensive care unit (ICU) developed multi-organ failure, especially hypoxemia-induced acute respiratory failure (ARF). Mortality in this series ranged from 17 to 40 %. Ventilation was required in 64&#x02013;100 % of the patients admitted to the ICU [<xref ref-type="bibr" rid="CR00143">3</xref>&#x02013;<xref ref-type="bibr" rid="CR00148">8</xref>], whether due to hypoxemia symptoms such as adult respiratory distress syndrome (ARDS) or to exacerbation of chronic pathologies such as cardiac failure or chronic obstructive pulmonary disease (COPD), which are often accompanied by hypercapnia. The need for invasive mechanical ventilation (IMV) was considered to be one of the factors linked to hospital mortality [<xref ref-type="bibr" rid="CR00146">6</xref>]. With regard to the kind of ventilation used, this varied depending on the series [<xref ref-type="bibr" rid="CR00143">3</xref>&#x02013;<xref ref-type="bibr" rid="CR00145">5</xref>, <xref ref-type="bibr" rid="CR00147">7</xref>, <xref ref-type="bibr" rid="CR00148">8</xref>], although IMV was more commonly used than noninvasive ventilation (NIV). Also, there was a high failure rate (&#x0003e;70 %) in the case of NIV (Table <xref rid="Tab00141" ref-type="table">14.1</xref>). Given the low success rate of NIV [<xref ref-type="bibr" rid="CR00143">3</xref>], the controversial indications for using it in hypoxemic patients, and the risk of facilitating aerosol-borne spread of the virus and thus the danger to health care personnel, in 2009 scientific societies [<xref ref-type="bibr" rid="CR00149">9</xref>] made various recommendations concerning its use. One was that NIV was best applied: (1) in patients with hypercapnia-exacerbated COPD; (2) in patients whose heart diseases were accompanied by acute pulmonary edema; (3) to prevent postextubation failure. In the case of patients with acute hypoxemia and the associated risk of organ failure, prolonged NIV treatment may lead to risky intubation. Accordingly, NIV should not be used as a matter of course.<table-wrap id="Tab00141"><label>Table 14.1</label><caption><p>Outcomes of various ventilation systems and mortality rates in several series</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Study</th><th rowspan="2">Not ventilated</th><th rowspan="2">IMV</th><th rowspan="2">NIV</th><th rowspan="2">NIV failure</th><th>Mortality</th><th rowspan="2">Mortality<sup>a</sup>
</th></tr><tr><th>Day 28</th></tr></thead><tbody><tr><td><p>ANZIC [<xref ref-type="bibr" rid="CR00146">6</xref>], <italic>n</italic>(%)</p><p>(<italic>n</italic>&#x02009;=&#x02009;722)</p></td><td>250 (26)<sup>b</sup>
</td><td>456 (64)<sup>b</sup>
</td><td>NR</td><td>NR</td><td>NR</td><td>103 (14)</td></tr><tr><td><p>Estenssoro [<xref ref-type="bibr" rid="CR00148">8</xref>], <italic>n</italic>(%)</p><p>(<italic>n</italic>&#x02009;=&#x02009;337)</p></td><td>&#x02013;</td><td>273 (81)</td><td>64 (19)</td><td>&#x02013;</td><td>NR</td><td>156 (46)</td></tr><tr><td><p>Kumar [<xref ref-type="bibr" rid="CR00143">3</xref>], <italic>n</italic>(%)</p><p>(<italic>n</italic>&#x02009;=&#x02009;168)</p></td><td>32 (19)</td><td>81(48)</td><td>55(33)</td><td>47 (85)</td><td>24 (14)</td><td>29 (17)</td></tr><tr><td><p>Dom&#x000ed;nguez [<xref ref-type="bibr" rid="CR00144">4</xref>], <italic>n</italic>(%)</p><p>(<italic>n</italic>&#x02009;=&#x02009;58)</p></td><td>4 (7)</td><td>32 (55)</td><td>22 (38)</td><td>16 (72)</td><td>23 (40)</td><td>24 (41)</td></tr><tr><td><p>Rello [<xref ref-type="bibr" rid="CR00145">5</xref>], <italic>n</italic>(%)</p><p>(<italic>n</italic>&#x02009;=&#x02009;32)</p></td><td>8 (25)</td><td>16 (50)</td><td>8 (25)</td><td>6 (75)</td><td>NR</td><td>8 (25)</td></tr><tr><td><p>Villab&#x000f3;n,<sup>c</sup>
<italic>n</italic>(%)</p><p>(<italic>n</italic>&#x02009;=&#x02009;12)</p></td><td>&#x02013;</td><td>12</td><td>0</td><td>0</td><td>NR</td><td>4 (33)</td></tr><tr><td><p>Villamagua,<sup>c</sup>
<italic>n</italic>(%)</p><p>(<italic>n</italic>&#x02009;=&#x02009;15)</p></td><td>&#x02013;</td><td>15</td><td>0</td><td>0</td><td>NR</td><td>6 (40)</td></tr><tr><td rowspan="2"><p>Belenguer [<xref ref-type="bibr" rid="CR001410">10</xref>], <italic>n</italic>(%)</p><p>(<italic>n</italic>&#x02009;=&#x02009;10)</p></td><td>1(10)</td><td>2 (20)</td><td>7 (70)</td><td>2 (20)</td><td>NR</td><td>1 (10)</td></tr><tr><td>0</td><td>0</td><td>5<sup>d</sup>
</td><td>0</td><td>NR</td><td>0</td></tr></tbody></table><table-wrap-foot><p>
<italic>n</italic>, number of patients</p><p>
<italic>IMV</italic> invasive mechanical ventilation, <italic>NIV</italic> noninvasive ventilation, <italic>NR</italic> not reported</p><p>
<sup>a</sup>Mortality on day 60 and global mortality</p><p>
<sup>b</sup>
<italic>n</italic>&#x02009;=&#x02009;706</p><p>
<sup>c</sup>Data from Colombian and Ecuatorian series published by Rodr&#x000ed;guez et al. [<xref ref-type="bibr" rid="CR00147">7</xref>]</p><p>
<sup>d</sup>Data corresponding to hypoxemic group</p></table-wrap-foot></table-wrap>
</p><p>Our experience [<xref ref-type="bibr" rid="CR001410">10</xref>] produced results that differed from those in previously published studies on the use of NIV. Ten patients (2009&#x02013;2010) were entered in the national register of virus influenza A(H1N1) of the Infectious Diseases Work Group of the Spanish Society of Intensive and Critical Care Medicine and Coronary Units. Seven of these patients displayed primary viral pneumonia (Table <xref rid="Tab00142" ref-type="table">14.2</xref>). Most of the patients were young and otherwise healthy, but excess weight (40 %) and pregnancy (two patients) were notable factors. Seven patients (7/10, 70 %) underwent NIV. Two patients were intubated on admission, and one did not require mechanical ventilation. Overall mortality was 10 % (one patient). This patient had been transferred from another hospital with multi-organ failure and died 24 h after admission. A group of five patients with hypoxemia were analyzed (Table <xref rid="Tab00142" ref-type="table">14.2</xref>) especially in connection with radiological signs of hypoxemia and liver failure. All patients were treated with NIV and continuous positive airway pressure (CPAP). Orotracheal intubation was not required in any cases, and no patients died in the ICU or during the hospital stay (Tables <xref rid="Tab00141" ref-type="table">14.1</xref> and <xref rid="Tab00142" ref-type="table">14.2</xref>). The mean interval from the onset of symptoms to ICU or hospital admission was 5 days.<table-wrap id="Tab00142"><label>Table 14.2</label><caption><p>Baseline characteristics of comorbidity, pulmonary disease, laboratory and outcomes of patients admitted to the ICU</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Parameters</th><th>Global (<italic>n</italic>&#x02009;=&#x02009;10)</th><th>Hypoxemic Group (<italic>n</italic>&#x02009;=&#x02009;5)</th></tr></thead><tbody><tr><td>Sex, men (<italic>n</italic>&#x02009;=&#x02009;10), <italic>n</italic> (%)</td><td>5 (50)</td><td>3 (60)</td></tr><tr><td>Age, years<sup>a</sup>
</td><td>38 (27&#x02009;&#x02212;&#x02009;47)</td><td>45 (27&#x02009;&#x02212;&#x02009;48)</td></tr><tr><td>SOFA score<sup>a</sup>
</td><td>4 (3&#x02009;&#x02212;&#x02009;6)</td><td>4 (3&#x02009;&#x02212;&#x02009;4)</td></tr><tr><td>APACHE II score<sup>a</sup>
</td><td>8 (7&#x02009;&#x02212;&#x02009;16)</td><td>8 (6&#x02009;&#x02212;&#x02009;12)</td></tr><tr><td>Multi-organ failure at admission, <italic>n</italic> (%)</td><td>1 (10)</td><td>0</td></tr><tr><td>
<italic>Setting</italic>
</td><td/><td/></tr><tr><td>&#x02003;Emergency room, <italic>n</italic> (%)</td><td>7 (70)</td><td>4 (80)</td></tr><tr><td>&#x02003;ICU at another hospital, <italic>n</italic> (%)</td><td>2 (20)</td><td/></tr><tr><td>&#x02003;Ward, <italic>n</italic> (%)</td><td>1 (10)</td><td>1 (20)</td></tr><tr><td>
<italic>Co-morbidities</italic>
</td><td/><td/></tr><tr><td>&#x02003;Pregnancy, <italic>n</italic> (%)</td><td>2 (20)</td><td>0</td></tr><tr><td>&#x02003;Hypertension, <italic>n</italic> (%)</td><td>1 (10)</td><td>1 (20)</td></tr><tr><td>&#x02003;Smoking, <italic>n</italic> (%)</td><td>1 (10)</td><td>1 (20)</td></tr><tr><td>&#x02003;Obesity, <italic>n</italic> (%)</td><td>4 (40)</td><td>4 (80)</td></tr><tr><td>&#x02003;Castleman disease</td><td>1 (10)</td><td>0</td></tr><tr><td>
<italic>Pulmonar infection</italic>
</td><td/><td/></tr><tr><td>&#x02003;Viral primary pneumonia</td><td>7 (70)</td><td>5 (100)</td></tr><tr><td>&#x02003;Acute asthma</td><td>1 (10)</td><td>&#x02013;</td></tr><tr><td>&#x02003;Ventilatory insufficiency</td><td>1 (10)</td><td>&#x02013;</td></tr><tr><td>&#x02003;Drug intoxication</td><td>1 (10)</td><td>&#x02013;</td></tr><tr><td>
<italic>Opacity on initial chest radiograph, n</italic> (%)</td><td/><td/></tr><tr><td>&#x02003;1/4 quadrants</td><td>3 (30)</td><td>0</td></tr><tr><td>&#x02003;2/4 quadrants</td><td>2 (20)</td><td>1 (20)</td></tr><tr><td>&#x02003;3/4 quadrants</td><td>2 (20)</td><td>2 (40)</td></tr><tr><td>&#x02003;4/4 quadrants</td><td>3 (30)</td><td>2 (40)</td></tr><tr><td>
<italic>Laboratory tests</italic>
</td><td/><td/></tr><tr><td>&#x02003;Lactate dehydrogenase,<sup>a</sup> UI/L</td><td>934 (448&#x02009;&#x02212;&#x02009;2,503)</td><td>934 (772&#x02009;&#x02212;&#x02009;2,503)</td></tr><tr><td>&#x02003;Alanine aminotransferase,<sup>a</sup> UI/L</td><td>63 (14&#x02009;&#x02212;&#x02009;76)</td><td>72 (45&#x02009;&#x02212;&#x02009;406)</td></tr><tr><td>&#x02003;Leukocytes,<sup>a</sup> per mm<sup>3</sup>
</td><td>13,150 (4,375&#x02009;&#x02212;&#x02009;18,125)</td><td>4,400 (4,150&#x02009;&#x02212;&#x02009;9,750)</td></tr><tr><td>&#x02003;Platelets,<sup>a</sup> per mm<sup>3</sup>
</td><td>185,500 (128,750&#x02009;&#x02212;&#x02009;274,500)</td><td>165,000 (131,000&#x02009;&#x02212;&#x02009;238,000)</td></tr><tr><td>
<italic>Ventilatory therapy on admission</italic>
</td><td/><td/></tr><tr><td>NIV <italic>n</italic> total (%)/<italic>n</italic> total failure (%)</td><td>7 (70)/2 (28)</td><td>5 (100)</td></tr><tr><td>&#x02003;Viral primary pneumonia</td><td>5 (71)/0</td><td>5 (100)</td></tr><tr><td>&#x02003;Acute asthma</td><td>1 (14.5)/1</td><td>0</td></tr><tr><td>&#x02003;Ventilatory insufficiency</td><td>1 (14.5)/1</td><td>0</td></tr><tr><td>IMV<sup>b</sup>
</td><td>2 (20)</td><td>0</td></tr><tr><td>Not ventilated</td><td>1 (10)</td><td>0</td></tr><tr><td>
<italic>Mortality, n</italic> (%)</td><td>1 (10)</td><td>0</td></tr></tbody></table><table-wrap-foot><p>
<italic>SOFA</italic> Sequential Organ Failure Assessment, <italic>APACHE</italic> Acute Physiology and Chronic Health Evaluation, <italic>ICU</italic> intensive care unit, <italic>NIV</italic> noninvasive ventilation, <italic>IMV</italic> invasive mechanical ventilation</p><p>
<italic>n</italic> number of patients</p><p>
<sup>a</sup>Median and interquartile index 25&#x02013;75, rest percentage</p><p>
<sup>b</sup>Viral primary pneumonia (one case) and drug intoxication (one case)</p></table-wrap-foot></table-wrap>
</p><p>Our tentative explanations for these highly satisfactory results are (1) the virtual absence of co-morbidity in a relatively young group of patients whose only adverse factors were excess weight and pregnancy (according to most series) [<xref ref-type="bibr" rid="CR00145">5</xref>&#x02013;<xref ref-type="bibr" rid="CR00148">8</xref>]; (2) a low organ-failure score on the Sepsis-Related Organ Failure Assessment (SOFA) scale&#x02014;on which hypoxemic respiratory failure was the most salient problem&#x02014;compared with the scores in other series [<xref ref-type="bibr" rid="CR00143">3</xref>&#x02013;<xref ref-type="bibr" rid="CR00145">5</xref>, <xref ref-type="bibr" rid="CR00147">7</xref>]; (3) the heightened awareness of health personnel, who had received health-authority guidelines to the effect that patients with pulmonary infiltrates and significant hypoxemia were to be admitted to the ICU straightaway to receive assisted ventilation. That is why our intervals to ICU admission are similar or lower than those in previously published studies [<xref ref-type="bibr" rid="CR00143">3</xref>, <xref ref-type="bibr" rid="CR00144">4</xref>, <xref ref-type="bibr" rid="CR00147">7</xref>] given that, with one exception, the patients were not placed in wards first. Similar to our results, the Argentina series [<xref ref-type="bibr" rid="CR00148">8</xref>] showed that 64 patients were treated with NIV to good effect. In that case, NIV boosted patient survival (24 % vs. 13 %, <italic>p</italic>&#x02009;=&#x02009;0.02). These data support the idea that greater use of NIV might have reduced the need for IMV and quite possibly the mortality rate, but this is of course no more than a supposition.</p><p>There are considerable disparities in the way NIV is used, but the published series [<xref ref-type="bibr" rid="CR00143">3</xref>&#x02013;<xref ref-type="bibr" rid="CR00147">7</xref>] show a high failure rate. By contrast, our results [<xref ref-type="bibr" rid="CR001410">10</xref>] showed successful NIV-based treatment. We therefore recommend early NIV/CPAP treatment for at least a few hours in young patients with pneumonia-induced hypoxemia caused by type A influenza and where no organ failure is apparent on the SOFA scale. This does not mean that NIV is an alternative to IMV but, rather, that clinically well-placed patients may benefit from NIV for treating ARF. If there is no improvement or the patient suffers from organ dysfunction, it is best to proceed with orotracheal intubation to prevent death&#x02014;a course of action recommended in one series [<xref ref-type="bibr" rid="CR00145">5</xref>], where there was a higher mortality rate among patients in which NIV failed than among those who had been intubated from the outset.</p><sec id="d29e1204"><title>Key Recommendations</title><p>
<list list-type="bullet"><list-item><p>Patients affected by virus influenza A(H1N1) and displaying multi-organ failure (respiratory, renal, hemodynamic, hepatic) should be admitted to the ICU.</p></list-item><list-item><p>Most patients with pulmonary infiltrates and ARF should undergo mechanical ventilation in an ICU, with the option of round-the-clock invasive or noninvasive assisted ventilation.</p></list-item><list-item><p>Invasive mechanical ventilation is &#x0201c;the gold standard&#x0201d; for treating ARF.</p></list-item><list-item><p>Early application of NIV can be recommended for young patients with organ failure as measured by the SOFA scale where hypoxemic ARF is the main problem.</p></list-item></list>
</p></sec></sec></body><back><ref-list id="Bib00141"><title>References</title><ref id="CR00141"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morens</surname><given-names>DM</given-names></name><name><surname>Taubenberger</surname><given-names>JK</given-names></name><name><surname>Harvey</surname><given-names>HA</given-names></name><name><surname>Memoli</surname><given-names>MJ</given-names></name></person-group><article-title>The 1918 influenza pandemic: lessons for 2009 and the future</article-title><source>Crit Care Med</source><year>2010</year><volume>38</volume><issue>Suppl</issue><fpage>e10</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1097/CCM.0b013e3181ceb25b</pub-id><?supplied-pmid 20048675?><pub-id pub-id-type="pmid">20048675</pub-id></element-citation></ref><ref id="CR00142"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maritz</surname><given-names>J</given-names></name><name><surname>Maree</surname><given-names>L</given-names></name><name><surname>Presier</surname><given-names>W</given-names></name></person-group><article-title>Pandemic influenza A (H1N1) 2009: the experience of the first six months</article-title><source>Clin Chem Lab Med</source><year>2010</year><volume>48</volume><fpage>11</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1515/CCLM.2010.023</pub-id><?supplied-pmid 20025556?><pub-id pub-id-type="pmid">20025556</pub-id></element-citation></ref><ref id="CR00143"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Zarychanski</surname><given-names>R</given-names></name><name><surname>Pinto</surname><given-names>R</given-names></name><name><surname>Cook</surname><given-names>D</given-names></name><name><surname>Marshall</surname><given-names>J</given-names></name><name><surname>Lacroix</surname><given-names>J</given-names></name><etal/></person-group><article-title>Critically ill patients with 2009 influenza A (H1N1) infection in Canada</article-title><source>JAMA</source><year>2009</year><volume>302</volume><fpage>1872</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1001/jama.2009.1496</pub-id><?supplied-pmid 19822627?><pub-id pub-id-type="pmid">19822627</pub-id></element-citation></ref><ref id="CR00144"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dom&#x000ed;nguez-Cherit</surname><given-names>G</given-names></name><name><surname>Lapinsky</surname><given-names>SE</given-names></name><name><surname>Macias</surname><given-names>A</given-names></name><name><surname>Pinto</surname><given-names>R</given-names></name><name><surname>Espinosa-P&#x000e9;rez</surname><given-names>L</given-names></name><etal/></person-group><article-title>Critically ill patients with 2009 influenza A (H1N1) infection in Mexico</article-title><source>JAMA</source><year>2009</year><volume>302</volume><fpage>1880</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1001/jama.2009.1536</pub-id><?supplied-pmid 19822626?><pub-id pub-id-type="pmid">19822626</pub-id></element-citation></ref><ref id="CR00145"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rello</surname><given-names>J</given-names></name><name><surname>Rodr&#x000ed;guez</surname><given-names>A</given-names></name><name><surname>Iba&#x000f1;ez</surname><given-names>P</given-names></name><name><surname>Socias</surname><given-names>L</given-names></name><name><surname>Cebrian</surname><given-names>J</given-names></name><name><surname>Marques</surname><given-names>A</given-names></name><etal/></person-group><article-title>Intensive care adults patients with severe respiratory failure caused by influenza A (H1N1)v in Spain</article-title><source>Crit Care</source><year>2009</year><volume>13</volume><fpage>R148</fpage><pub-id pub-id-type="doi">10.1186/cc8044</pub-id><?supplied-pmid 19747383?><pub-id pub-id-type="pmid">19747383</pub-id></element-citation></ref><ref id="CR00146"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>ANZIC The Influenza Investigators</collab></person-group><article-title>Critical care services and 2009 H1N1 influenza in Australia and New Zealand</article-title><source>N Engl J Med</source><year>2009</year><volume>361</volume><fpage>1925</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0908481</pub-id><pub-id pub-id-type="pmid">19815860</pub-id></element-citation></ref><ref id="CR00147"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodr&#x000ed;guez</surname><given-names>A</given-names></name><name><surname>Soc&#x000ed;as</surname><given-names>L</given-names></name><name><surname>Guerrero</surname><given-names>JE</given-names></name><name><surname>Figueira</surname><given-names>JC</given-names></name><name><surname>Gonz&#x000e1;lez</surname><given-names>N</given-names></name><name><surname>Marav&#x000ed;-Poma</surname><given-names>E</given-names></name><etal/></person-group><article-title>Gripe A pand&#x000e9;mica en una unidad de cuidados intensivos: experiencia en Espa&#x000f1;a y Latinoamerica (Grupo Espa&#x000f1;ol de Trabajo de Gripe A Grave/Sociedad Espa&#x000f1;ola de Medicina Intensiva, Cr&#x000ed;tica y Unidades Coronarias)</article-title><source>Med Intensiva</source><year>2010</year><volume>34</volume><fpage>87</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1016/j.medin.2009.12.005</pub-id><?supplied-pmid 20061066?><pub-id pub-id-type="pmid">20061066</pub-id></element-citation></ref><ref id="CR00148"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Estenssoro</surname><given-names>E</given-names></name><name><surname>R&#x000ed;os</surname><given-names>FG</given-names></name><name><surname>Apeztegu&#x000ed;a</surname><given-names>C</given-names></name><name><surname>Reina</surname><given-names>R</given-names></name><name><surname>Neira</surname><given-names>J</given-names></name><name><surname>Ceraso</surname><given-names>DH</given-names></name><etal/></person-group><article-title>Pandemic 2009 influenza A in Argentina. A study of 337 patients on mechanical ventilation</article-title><source>Am J Respir Crit Care Med</source><year>2010</year><volume>182</volume><fpage>41</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1164/201001-0037OC</pub-id><?supplied-pmid 20203241?><pub-id pub-id-type="pmid">20203241</pub-id></element-citation></ref><ref id="CR00149"><label>9.</label><mixed-citation publication-type="other">Conti G, Larrson A, Nava S, Navalesi P. On the role of non-invasive (NIV) to treat patients during the H1N1 influenza pandemic. Disponible en: <ext-link ext-link-type="uri" xlink:href="http://dev.ersnet.org/uploads/Document/63/WEB_CHEMIN_5410_1258624142.pdf">http://dev.ersnet.org/uploads/Document/63/WEB_CHEMIN_5410_1258624142.pdf</ext-link>.</mixed-citation></ref><ref id="CR001410"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belenguer-Muncharaz</surname><given-names>A</given-names></name><name><surname>Reig-Valero</surname><given-names>R</given-names></name><name><surname>Altaba-Tena</surname><given-names>S</given-names></name><name><surname>Casero-Roig</surname><given-names>P</given-names></name><name><surname>Ferr&#x000e1;ndiz-Sell-es</surname><given-names>A</given-names></name></person-group><article-title>Utilizaci&#x000f3;n de la ventilaci&#x000f3;n mec&#x000e1;nica no invasiva en neumon&#x000ed;a grave por virus H1N1</article-title><source>Med Intensiva</source><year>2011</year><volume>38</volume><issue>5</issue><fpage>470</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.medin.2011.04.001</pub-id></element-citation></ref></ref-list></back></article>